Greenwich LifeSciences (GLSI) Research & Development (2019 - 2025)
Greenwich LifeSciences (GLSI) posted Research & Development of $8.3 million for Q4 2025, up 152.99% on a QoQ basis from $3.3 million in Q3 2025, and down 4.84% year-over-year from $8.7 million in Q4 2024.
Greenwich LifeSciences (GLSI) Research & Development (2019 - 2025) Analysis & Trends
Greenwich LifeSciences' Research & Development history runs 7 years deep, the most recent figure standing at $8.3 million for Q4 2025.
- Quarterly Research & Development fell 4.84% year-over-year to $8.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $17.2 million (up 11.24% YoY) and the FY2025 annual result came in at $17.2 million, up 11.24% from the prior year.
- Research & Development was $8.3 million for Q4 2025 at Greenwich LifeSciences, up from $3.3 million in the prior quarter.
- Across five years, Research & Development topped out at $8.7 million in Q4 2024 and bottomed at $281977.0 in Q1 2021.
- A 5-year average of $2.5 million and a median of $2.2 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development jumped 488.99% — and 2023, when it slipped 5.09%.
- Greenwich LifeSciences' Research & Development stood at $2.1 million in 2021, then grew by 19.1% to $2.5 million in 2022, then slipped by 5.09% to $2.3 million in 2023, then soared by 272.3% to $8.7 million in 2024, then retreated by 4.84% to $8.3 million in 2025.
- Business Quant data shows GLSI's Research & Development at $8.3 million in Q4 2025, $3.3 million in Q3 2025, and $3.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 541.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -2.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.37 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 343.97 Mn |
| 10 | Greenwich LifeSciences | 178.53 Mn | 178.53 Mn | - | 8.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.27 Mn |
| Sep 30, 2025 | 3.27 Mn |
| Jun 30, 2025 | 3.42 Mn |
| Mar 31, 2025 | 2.27 Mn |
| Dec 31, 2024 | 8.69 Mn |
| Sep 30, 2024 | 2.29 Mn |
| Jun 30, 2024 | 2.31 Mn |
| Mar 31, 2024 | 2.19 Mn |
| Dec 31, 2023 | 2.33 Mn |
| Sep 30, 2023 | 2.16 Mn |
| Jun 30, 2023 | 1.38 Mn |
| Mar 31, 2023 | 1.83 Mn |
| Dec 31, 2022 | 2.46 Mn |
| Sep 30, 2022 | 1.72 Mn |
| Jun 30, 2022 | 633,250.00 |
| Mar 31, 2022 | 1.66 Mn |
| Dec 31, 2021 | 2.06 Mn |
| Sep 30, 2021 | 657,096.00 |
| Jun 30, 2021 | 556,534.00 |
| Mar 31, 2021 | 281,977.00 |